Liothyronine (T3) and Trenbolone Interaction: Avoid | Peptide Database

Join others researching Dutasteride — share findings, ask questions, and learn from real experiences Dutasteride is a potent dual 5-alpha reductase inhibitor that blocks both Type I and Type II isoforms of the enzyme responsible for converting testosterone to dihydrotestosterone (DHT). FDA-approved at 0.5mg daily for benign prostatic hyperplasia (BPH) under the brand name Avodart, it is widely used off-label for the treatment of androgenetic alopecia (male pattern hair loss). By inhibiting both isoforms, dutasteride achieves approximately 90% suppression of serum DHT, compared to roughly 70% with finasteride, which blocks only the Type II isoform. This greater DHT suppression translates to potentially superior hair regrowth outcomes in head-to-head comparisons, though it also carries a somewhat higher risk of DHT-related side effects. Dutasteride has an exceptionally long half-life of approximately 5 weeks, meaning it takes several months to reach steady-state levels and equally long for effects to fully wash out after discontinuation. Dutasteride competitively inhibits both the Type I and Type II isoforms of the enzyme 5-alpha reductase. Type II is the predominant isoform in the prostate and hair follicles, while Type I is found primarily in the skin, sebaceous glands, and liver. By blocking both isoforms, dutasteride suppresses serum DHT levels by approximately 90% at the standard 0.5mg dose, compared to the roughly 70% suppression achieved by finasteride (which blocks only Type II). This near-complete DHT suppression more effectively reduces the androgenic stimulus driving follicular miniaturization in genetically susceptible individuals. The exceptionally long elimination half-life of approximately 5 weeks is due to extensive tissue binding and slow clearance. Serum testosterone may increase modestly (10-20%) as a compensatory response to the pronounced reduction in DHT, though this increase remains within the normal physiological range for most men.

Raloxifene is considered the most effective SERM for reversing existing gynecomastia. Its strong antagonism at breast tissue estrogen receptors directly blocks the estradiol signaling that drives glandular proliferation. Clinical and anecdotal evidence consistently favors raloxifene over tamoxifen for reducing established gynecomastia tissue. Blocks estrogen receptor activation in breast tissue during aromatizable steroid cycles without reducing systemic estrogen levels. Preferred over tamoxifen when the primary goal is gynecomastia prevention rather than HPTA stimulation. FDA-approved for prevention and treatment of postmenopausal osteoporosis. Raloxifene acts as an estrogen agonist in bone tissue, maintaining bone mineral density and reducing the risk of vertebral fractures. The MORE trial demonstrated a 30-50% reduction in vertebral fracture risk. FDA-approved for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of breast cancer. The STAR trial demonstrated equivalent efficacy to tamoxifen for invasive breast cancer risk reduction with fewer side effects.